Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Abstract Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas, Stefan Rieken
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2019-11-01
Series:BMC Cancer
Assuntos:
Non-small cell lung cancer
Immunotherapy
Radioimmunotherapy
Abscopal effect
PD-1
Nivolumab
Acceso en liña:http://link.springer.com/article/10.1186/s12885-019-6205-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares